For the quarter ending 2025-09-30, YBGJ had $510 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -902,288 | - |
| Depreciation and amortization | 43,588 | 89,766 |
| Loss on obsolete inventory | 0 | 0 |
| Receivables | 3,718 | 46,979 |
| Prepaid expense | 39,794 | -45,430 |
| Inventory | 697 | -697 |
| Net loss | - | -541,059 |
| Due from related parties | 5,235 | -5,235 |
| Lease security deposit | -296 | 80,018 |
| Accounts payable and accrued expenses | -93,298 | 12,662 |
| Advances from prospective customers/distributors | 2,735 | 8,002 |
| Cash receipts from related parties | 0 | - |
| Net cash used in operating activities | -359,056 | -354,994 |
| Proceeds for sale of equipment | 0 | 79,904 |
| Net cash provided in investing activities | 0 | 79,904 |
| Advances from related parties (net) | 0 | 473,919 |
| Capital contributions to subsidiary | 0 | 0 |
| Net cash provided by financing activities | 0 | 473,919 |
| Effect of exchange rate changes | 359,566 | -195,428 |
| Net increase (decrease) in cash | 510 | 3,401 |
| Cash and cash equivalents at beginning of period | 7,015 | - |
| Cash and cash equivalents at end of period | 10,926 | - |
Yubo International Biotech Ltd (YBGJ)
Yubo International Biotech Ltd (YBGJ)